We are excited to announce that we received approval to participate in a clinical trial to test a new drug for macular degeneration. Clinical trial Phase 3 Safety and Efficacy Study of Fovista Intravitreous Administration in Combination with Either Avastin or Eylea Compared to Avastin or Eylea Monotherapy is an international research project to investigate the effectiveness of a new treatment called Fovista® for “wet” age-related macular degeneration. Illinois Eye Center is one of a number of locations throughout the United States and the second in Illinois participating in the trial for the new AMD drug. Several other countries such as Portugal, Israel, Spain, Hungary and Finland are part of the international research locations.
Early clinical trial data demonstrated promising results in patients who received the drug. This clinical trial is ongoing and we are actively recruiting patients who meet the criteria.
Our team, led by Dr. Han, Principal Investigator, and Dr. Pete Lagouros, Sub-Investigator, has been working hard over the past few months to complete staff and equipment certification. We will continue to evaluate our patient base for additional participants as we move forward.